Hemal Mehta, MBBS MD(Cantab.)
Professional Affiliations
Academic Appointments- Adjunct Professor, University of Notre Dame Australia, Sydney, NSW, Australia
- Clinical Associate Professor, University of Sydney, Sydney, NSW, Australia
- Strathfield Retina Clinic, Sydney, NSW, Australia - Co-director of Clinical Trials Research
- Sydney Retina Clinic, Sydney, NSW, Australia
- Central Coast Eye Specialists, NSW, Australia
Education and Training
- Retinal fellowship
- Sydney Eye Hospital, Sydney, NSW, Australia
- Retinal fellowship
- Moorfields Eye Hospital, London, England, United Kingdom
- Ophthalmology residency
- London School of Ophthalmology , London, England, UK
- Medical School
- University College London , London, England, UK
- Medical School
- University of Cambridge , Cambridge, England, UK
Biography
Hemal Mehta is an academic ophthalmologist specialising in the management of macula diseases. He has expertise in retinal clinical trials, tracking real-world treatment outcomes and retinal imaging. Hemal is a retinal specialist on the Therapeutics Committee of the Royal Australian and New Zealand College of Ophthalmologists and is a medical retina Section Editor for the Journal Eye. He is a Clinical Associate Professor with Faculty of Medicine and Health, University of Sydney and on the Steering Committee of the Fight Retinal Blindness! (FRB!) project. He is an an advisor for the Royal College of Ophthalmologists of England national audit of age-related macular degeneration treatment outcomes. The clinical research during his previous fellowships at Sydney Eye Hospital and Moorfields Eye Hospital contributed to his MD research thesis (academically on par with a PhD) on ‘Novel endpoints in diabetic retinopathy clinical trials’ registered at Cambridge University. Hemal has over 70 peer-reviewed publications. He was awarded the Australian Vision Research RANZCO Primer Grant to support linking imaging with FRB! registry data. Hemal is Co-director of Clinical Trials Research at Strathfield Retina Clinic and has served as PI or Sub-PI in over 50 clinical trials. He is Adjunct Professor at University of Notre Dame Australia, co-leading the Ophthalmic Pathology Translational Research Group.